Buy Bromazolam Blister – 10x 2.5mg

Product Overview

Bromazolam Blister – 10x 2.5mg offers a brandless, high-purity (≥98%) triazolobenzodiazepine compound formulated exclusively for laboratory and analytical research applications. As a reference standard within the benzodiazepine class, it supports studies in pharmacokinetics, forensic analysis, and structural elucidation in professional environments. The blister format ensures dosage uniformity and ease of use in chromatographic workflows, maintaining integrity for qualified research protocols. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Bromazolam is identified by CAS number 71368-80-4, with the molecular formula C17H13BrN4 and molecular weight of 353.22 g/mol. Common synonyms include 8-bromo-1-methyl-6-phenyl-4H-triazolo[4,3-a]benzodiazepine, XLI-268, and DE(chloro)-bromo-alprazolam. Classified as an analytical reagent and novel benzodiazepine analog, it functions primarily as a reference material for mass spectrometry, NMR spectroscopy, and HPLC method development in research laboratories.

This compound’s systematic name, 8-bromo-1-methyl-6-phenyl-4H-s-triazolo[4,3-a]benzodiazepine, highlights its triazolo-fused structure, distinguishing it from related scaffolds. Researchers reference these identifiers for precise cataloging in databases like PubChem (CID 12562546) and ChemSpider. Its classification aligns with non-approved developmental chemicals used solely in non-clinical analytical contexts.

Chemical & Physical Characteristics

Bromazolam manifests as a crystalline solid, typically off-white to pale yellow, ideal for formulation into stable blister packs. It exhibits solubility in DMSO (up to 5 mg/mL), moderate solubility in ethanol and DMF, and lower solubility in aqueous buffers like PBS (pH 7.2). Predicted properties include a logP around 2.9, density of approximately 1.6 g/cm³, and a melting point suitable for solid-state analysis without decomposition under standard lab conditions.

The compound’s stability profile supports storage at -20°C for extended periods, with minimal degradation in inert atmospheres. Its InChI key (KCEIOBKDDQAYCM-UHFFFAOYSA-N) and SMILES notation (CC1=NN=C2N1C3=CC=C(Br)C=C3C(=NC2)C4=CC=CC=C4) aid computational modeling and spectral matching in research. Physical form consistency ensures reliable dissolution for LC-MS and GC-MS applications.

Vapor pressure remains low, classifying it as non-volatile, while UV absorbance characteristics (λmax in organic solvents) facilitate detection in analytical assays. These traits position Bromazolam as a robust standard for quantitative research.

Purity & Analytical Verification

Bromazolam Blister – 10x 2.5mg guarantees ≥98% purity, confirmed via High-Performance Liquid Chromatography (HPLC) at 254 nm, Gas Chromatography (GC-FID), Nuclear Magnetic Resonance (NMR) spectroscopy, and Liquid Chromatography-Mass Spectrometry (LC-MS). These orthogonal methods detect impurities below 0.5%, including related substances and residual solvents. Every blister pack includes traceability to a master COA, detailing peak purity (>99% by HPLC area) and isotopic distribution.

Routine verification employs USP-compliant protocols, with mass accuracy within 5 ppm on HRMS instruments. Researchers access full spectral libraries upon request, ensuring method validation compliance. This level of scrutiny eliminates batch variability, critical for calibration standards.

Quality Control & Batch Integrity

Batch production adheres to GMP-like standards for research chemicals, with each lot undergoing synthesis under nitrogen atmosphere, followed by recrystallization for homogeneity. Lot-specific numbering enables full traceback from raw materials (sourced to ≥99% intermediates) through final packaging. Third-party labs perform identity confirmation via FTIR and elemental analysis (CHN), aligning with ICH Q3A guidelines adapted for reagents.

Internal audits document yield consistency (85-95%), moisture content (<0.5% KF), and particle size distribution for uniform blister filling. Deviation from specs triggers quarantine, ensuring only qualified material reaches distribution. This framework builds researcher confidence in reproducibility across studies.

Retention samples from each batch allow retrospective testing, supporting long-term stability programs. Documentation packets include chromatograms, NMR traces, and ICP-MS for heavy metals (<10 ppm total).

Safety, Handling & Laboratory Precautions

Process Bromazolam Blister – 10x 2.5mg exclusively in certified fume hoods with PPE including chemical-resistant gloves (nitrile, 15 mil), splash goggles, face shields, and disposable lab coats. Limit manipulations to trained personnel in restricted-access labs equipped with spill kits and eyewash stations. Avoid skin contact, inhalation, or aerosol generation during transfer.

Secondary containment and grounded equipment prevent static hazards. In case of exposure, follow site-specific protocols referencing the provided SDS, which details GHS classifications (Acute Tox 3, Flam Liq potential). Neutralize spills with 5% sodium bicarbonate solution, followed by proper disposal as hazardous waste.​

Packaging, Labeling & Storage

The 10x 2.5mg blister pack employs pharmaceutical-grade PVC/PVDC foil with child-resistant, tamper-evident lidding for protection against moisture and light. Each blister unit seals individual doses, minimizing cross-contamination and facilitating serial dispensing in workflows. Labels feature scannable QR codes linking to batch COA, CAS 71368-80-4, purity statement, and research-use markings compliant with REACH and TSCA.

Outer secondary packaging uses HDPE bottles or foil pouches with desiccants. Store at -20°C in the dark, away from bases, oxidizers, and reducing agents; shelf life exceeds 24 months under these conditions. Avoid refrigeration cycles to prevent condensation.

Intended Research Use & Market Positioning

Bromazolam Blister – 10x 2.5mg targets analytical chemistry labs for LC-HRMS metabolite identification, forensic toxicology screening panels, and pharmaceutical R&D impurity profiling. Educational institutions employ it for benzodiazepine synthesis demonstrations and spectral interpretation courses. Industrial sectors leverage it in quality control for triazolo scaffold production and stability-indicating assays.

In reference material markets, it calibrates GC-MS libraries for novel psychoactive substance detection. High-throughput screening facilities benefit from the blister format for automated pipetting. Positioned as a premium, compliant alternative to custom synthesis, it serves global research networks excluding diagnostic contexts.

Ordering, Availability & Fulfillment

Stock levels for Bromazolam Blister – 10x 2.5mg support same-day dispatch for verified orders via WooCommerce platform with SSL encryption and 3DSecure. International fulfillment uses temperature-controlled carriers with full tracking and signature requirements. Bulk inquiries receive tiered pricing and dedicated account management.

Customer portal tracks shipments in real-time, with COA downloads and retest date notifications. Support responds within 24 hours for compliance queries or reissue requests, ensuring uninterrupted research timelines.​

Legal & Regulatory Disclaimer

Bromazolam Blister – 10x 2.5mg is sold strictly for research purposes only, not for human or veterinary use, clinical, diagnostic, or therapeutic applications. Buyers must ensure adherence to all local, national, and international laws regulating research chemicals, including DEA scheduling where applicable. This product ships only to licensed entities; export controls may apply. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.